Honasa Called Off a ₹135 Crore Acquisition Two Months After Announcing It

On 25 August 2026, Honasa Consumer told stock exchanges it had terminated its proposed acquisition of a 58% stake in Fluence Pharma, a nutraceuticals company, citing "non-fulfilment of closing conditions" under the share purchase agreement. Honasa did not say which condition went unmet.

The deal had been announced barely two months earlier, on 23 June 2026, at an enterprise value of roughly ₹135 crore. The structure was unusual for a full buyout: Honasa was to take 58% immediately, with the remaining 42% to follow in two tranches spread across the next five to seven years. Alongside the acquisition, Honasa had planned to set up a new wholly owned subsidiary, Honasa Health, to combine Fluence Pharma's clinical and dermatologist-led distribution with Honasa's own brand-building and digital reach.

What Honasa was actually buying

Fluence Pharma isn't a startup in the venture-funded sense. Founded in 2012 by Amit Bhusari and Dr Rajendra Singh Rajput, it sells hair and skin health supplements — under brands including Hair Fact, Skin Fact, and Pro Fact — almost entirely through a network of over 3,000 dermatologists, using a patented approach it calls Cyclical Nutrition Therapy. It has no funding rounds on record; it built this business on its own revenue.

That revenue was real: Honasa's own deal presentation put Fluence Pharma's FY26 revenue at around ₹40 crore, with an EBITDA margin above 20%, and more than 70% of that revenue coming from hair-focused products. A small, profitable, founder-run supplements business with a genuine prescriber network is exactly the kind of asset a D2C brand with strong distribution but no clinical credibility would want to buy rather than build.

The scale that makes "called off" read as discipline, not crisis

Here's the context most of the wire coverage on this deal skipped: ₹135 crore is a rounding error against where Honasa sits right now. The stock closed at ₹478.9 as of 18 August 2026, just below its 52-week high of ₹509.80, up 59.4% over six months. Honasa's market cap stands at roughly ₹15,828 crore. Its Q4 FY26 net profit jumped nearly 177% year over year to about ₹69 crore. That strength is also showing up in insider behaviour: co-founder Varun Alagh recently boosted his own stake in Honasa Consumer with a ₹50 crore block deal, the kind of move that doesn't usually accompany a company backing out of a deal for financial-distress reasons.

Put simply: this was a company sitting on a rallying stock and improving profitability, walking away from a deal worth less than 1% of its market cap because a contractual condition wasn't met. That is not the profile of a company in trouble backing out of a lifeline. It's a company that priced in optionality, and let the option lapse when the terms it wrote for itself weren't satisfied.

What we don't know, and won't guess

Honasa did not disclose which closing condition failed. It could be anything from a regulatory approval, to a financial covenant on Fluence Pharma's side, to a valuation-adjustment trigger built into the original agreement. None of the coverage of this story, including this one, has that detail, and inventing a plausible-sounding reason would be worse than leaving the gap open. What Honasa did say is that it "remains committed to its nutraceutical strategy" and will keep evaluating both organic and inorganic paths into the category. Read together with the scale point above, that reads as genuine: this was one specific bet that didn't clear diligence, not a retreat from the category.

Have more on why this deal actually fell through? Get in touch.